Tag Archives: Iterum Therapeutics

H.C. Wainwright Reaffirms Their Hold Rating on Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today. The company’s shares closed last Monday at $1.81. According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.5% and

H.C. Wainwright Keeps a Hold Rating on Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today. The company’s shares closed last Wednesday at $1.04, close to its 52-week low of $0.45. According to TipRanks.com, Arce is a 5-star analyst

Iterum Therapeutics (ITRM) Gets a Hold Rating from Leerink Partners

Leerink Partners analyst Ami Fadia maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) today and set a price target of $1.50. The company’s shares closed last Wednesday at $1.05. According to TipRanks.com, Fadia is a 2-star analyst

Iterum Therapeutics (ITRM) Receives a Hold from RBC Capital

In a report issued on August 6, Gregory Renza from RBC Capital maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $1.03, close to its

Iterum Therapeutics (ITRM) was Downgraded to a Hold Rating at RBC Capital

RBC Capital analyst Gregory Renza downgraded Iterum Therapeutics (ITRM – Research Report) to Hold today and set a price target of $2.00. The company’s shares closed last Monday at $1.70, close to its 52-week low of $1.40. According to TipRanks.com,

H.C. Wainwright Maintains a Buy Rating on Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics (ITRM – Research Report) today and set a price target of $9.00. The company’s shares closed last Thursday at $3.50. According to TipRanks.com, Arce is a 5-star analyst